PTC Therapeutics (PTCT) Projected to Release Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT) will likely be issuing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $0.2071 per share and revenue of $304.60 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.68. The business had revenue of $360.52 million for the quarter, compared to the consensus estimate of $298.63 million. PTC Therapeutics’s revenue was up 101.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.83) EPS. On average, analysts expect PTC Therapeutics to post $1.19 EPS for the current fiscal year and $1.90 EPS for the next fiscal year.

PTC Therapeutics Trading Up 0.8%

NASDAQ:PTCT opened at $61.07 on Tuesday. The firm’s fifty day simple moving average is $66.17 and its 200 day simple moving average is $71.08. PTC Therapeutics has a twelve month low of $58.80 and a twelve month high of $90.87.

Insider Buying and Selling

In related news, Director Glenn Steele, Jr. sold 12,000 shares of the company’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $65.16, for a total value of $781,920.00. Following the sale, the director directly owned 22,500 shares of the company’s stock, valued at $1,466,100. This represents a 34.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Schmertzler sold 2,500 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $59.61, for a total value of $149,025.00. Following the completion of the transaction, the director owned 1,291,594 shares of the company’s stock, valued at approximately $76,991,918.34. This trade represents a 0.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 77,370 shares of company stock valued at $5,322,261 over the last ninety days. Company insiders own 5.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on PTCT shares. Barclays upped their price objective on shares of PTC Therapeutics from $120.00 to $122.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Zacks Research lowered shares of PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Truist Financial started coverage on shares of PTC Therapeutics in a research report on Friday, October 16th. They set a “hold” rating and a $62.00 price target on the stock. Finally, Cantor Fitzgerald increased their price target on shares of PTC Therapeutics from $130.00 to $137.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.93.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.